文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

SGLT-2抑制剂、GLP-1受体激动剂与DPP-4抑制剂及2型糖尿病患者临床实践中高钾血症风险:基于人群的队列研究

SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study.
PubMed 文献 · BMJ · 2024-06-26
一句话结论2型糖尿病患者中,SGLT-2抑制剂与GLP-1受体激动剂较高钾血症风险低于DPP-4抑制剂,心衰、慢性肾病或使用盐皮质激素受体拮抗剂者绝对获益最大。

该研究基于美国2013年4月至2022年4月Medicare和两个大型商业保险数据库的理赔数据,采用活性对照、新使用者设计,1:1倾向性评分匹配2型糖尿病成人。结果显示,与DPP-4抑制剂相比,SGLT-2抑制剂高钾血症发生率更低(HR 0.75,95%CI 0.73-0.78),GLP-1受体激动剂亦更低(HR 0.79,95%CI 0.77-0.82);SGLT-2抑制剂较GLP-1受体激动剂略有降低(HR 0.92,95%CI 0.89-0.95)。3年绝对风险:SGLT-2抑制剂较DPP-4抑制剂低2.4%(4.6% vs 7.0%),GLP-1受体激动剂较DPP-4抑制剂低1.8%(5.7% vs 7.5%),SGLT-2抑制剂较GLP-1受体激动剂低1.2%(4.7% vs 6.0%)。心衰、慢性肾病或使用盐皮质激素受体拮抗剂者绝对获益最大,各具体药物结果一致,支持类效应。

要点

  • 与DPP-4抑制剂相比,SGLT-2抑制剂高钾血症发生率更低(HR 0.75,95%CI 0.73-0.78),GLP-1受体激动剂亦更低(HR 0.79,95%CI 0.77-0.82)。
  • SGLT-2抑制剂较GLP-1受体激动剂高钾血症发生率略有降低(HR 0.92,95%CI 0.89-0.95)。
  • 3年绝对风险:SGLT-2抑制剂4.6% vs DPP-4抑制剂7.0%(低2.4%,95%CI 2.1%-2.7%);GLP-1受体激动剂5.7% vs DPP-4抑制剂7.5%(低1.8%,95%CI 1.4%-2.1%);SGLT-2抑制剂4.7% vs GLP-1受体激动剂6.0%(低1.2%,95%CI 0.9%-1.5%)。
  • 心衰、慢性肾病或使用盐皮质激素受体拮抗剂者,SGLT-2抑制剂和GLP-1受体激动剂的绝对获益最大。
  • SGLT-2抑制剂(卡格列净、达格列净、恩格列净)和GLP-1受体激动剂(度拉糖肽、艾塞那肽、利拉鲁肽、司美格鲁肽)各具体药物结果一致,提示类效应。

适用人群与场景

  • 美国2013年4月至2022年4月Medicare和两个大型商业保险数据库中,新开始SGLT-2抑制剂、GLP-1受体激动剂或DPP-4抑制剂的2型糖尿病成人。
  • 1:1倾向性评分匹配队列:SGLT-2抑制剂 vs DPP-4抑制剂 n=778 908;GLP-1受体激动剂 vs DPP-4抑制剂 n=729 820;SGLT-2抑制剂 vs GLP-1受体激动剂 n=873 460。

研究设计与关键结果

  • 研究设计:基于人群的队列研究,采用活性对照、新使用者设计,数据来自美国Medicare和两个大型商业保险数据库,时间2013年4月至2022年4月。
  • 主要终点(住院或门诊诊断的高钾血症):SGLT-2抑制剂 vs DPP-4抑制剂 HR 0.75(95%CI 0.73-0.78);GLP-1受体激动剂 vs DPP-4抑制剂 HR 0.79(95%CI 0.77-0.82);SGLT-2抑制剂 vs GLP-1受体激动剂 HR 0.92(95%CI 0.89-0.95)。
  • 3年绝对风险:SGLT-2抑制剂4.6% vs DPP-4抑制剂7.0%,SGLT-2抑制剂低2.4%(95%CI 2.1%-2.7%);GLP-1受体激动剂5.7% vs DPP-4抑制剂7.5%,GLP-1受体激动剂低1.8%(95%CI 1.4%-2.1%);SGLT-2抑制剂4.7% vs GLP-1受体激动剂6.0%,SGLT-2抑制剂低1.2%(95%CI 0.9%-1.5%)。
  • 次要终点(血清钾≥5.5 mmol/L定义的高钾血症;住院或急诊诊断的高钾血症)结果与主要终点一致;按年龄、性别、种族、合并症、其他药物使用和糖化血红蛋白水平定义的亚组中,相对风险结果一致。
  • 绝对风险获益在合并心衰、慢性肾病或使用盐皮质激素受体拮抗剂者中最大。
  • 与DPP-4抑制剂相比,SGLT-2抑制剂(卡格列净、达格列净、恩格列净)和GLP-1受体激动剂(度拉糖肽、艾塞那肽、利拉鲁肽、司美格鲁肽)各具体药物均一致观察到较低的高钾血症发生率。

证据类型、等级与局限

  • 证据类型:基于人群的队列研究(活性对照、新使用者设计)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在2型糖尿病患者中,SGLT-2抑制剂和GLP-1受体激动剂与DPP-4抑制剂相比高钾血症风险更低,此获益在整体人群和相关亚组中一致。
  • SGLT-2抑制剂和GLP-1受体激动剂类内各具体药物结果一致,提示类效应;这些额外获益进一步支持其在2型糖尿病患者中的使用,尤其是高钾血症风险者(作者认为)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: To evaluate the comparative effectiveness of sodium-glucose cotransporter-2 (SGLT-2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and dipeptidyl peptidase-4 (DPP-4) inhibitors in preventing hyperkalemia in people with type 2 diabetes in routine clinical practice.

DESIGN: Population based cohort study with active-comparator, new user design.

SETTING: Claims data from Medicare and two large commercial insurance databases in the United States from April 2013 to April 2022.

PARTICIPANTS: 1:1 propensity score matched adults with type 2 diabetes newly starting SGLT-2 inhibitors versus DPP-4 inhibitors (n=778 908), GLP-1 receptor agonists versus DPP-4 inhibitors (n=729 820), and SGLT-2 inhibitors versus GLP-1 receptor agonists (n=873 460).

MAIN OUTCOME MEASURES: Hyperkalemia diagnosis in the inpatient or outpatient setting. Secondary outcomes were hyperkalemia defined as serum potassium levels ≥5.5 mmol/L and hyperkalemia diagnosis in the inpatient or emergency department setting.

RESULTS: Starting SGLT-2 inhibitor treatment was associated with a lower rate of hyperkalemia than DPP-4 inhibitor treatment (hazard ratio 0.75, 95% confidence interval (CI) 0.73 to 0.78) and a slight reduction in rate compared with GLP-1 receptor agonists (0.92, 0.89 to 0.95). Use of GLP-1 receptor agonists was associated with a lower rate of hyperkalemia than DPP-4 inhibitors (0.79, 0.77 to 0.82). The three year absolute risk was 2.4% (95% CI 2.1% to 2.7%) lower for SGLT-2 inhibitors than DPP-4 inhibitors (4.6% v 7.0%), 1.8% (1.4% to 2.1%) lower for GLP-1 receptor agonists than DPP-4 inhibitors (5.7% v 7.5%), and 1.2% (0.9% to 1.5%) lower for SGLT-2 inhibitors than GLP-1 receptor agonists (4.7% v 6.0%). Findings were consistent for the secondary outcomes and among subgroups defined by age, sex, race, medical conditions, other drug use, and hemoglobin A1c levels on the relative scale. Benefits for SGLT-2 inhibitors and GLP-1 receptor agonists on the absolute scale were largest for those with heart failure, chronic kidney disease, or those using mineralocorticoid receptor antagonists. Compared with DPP-4 inhibitors, the lower rate of hyperkalemia was consistently observed across individual agents in the SGLT-2 inhibitor (canagliflozin, dapagliflozin, empagliflozin) and GLP-1 receptor agonist (dulaglutide, exenatide, liraglutide, semaglutide) classes.

CONCLUSIONS: In people with type 2 diabetes, SGLT-2 inhibitors and GLP-1 receptor agonists were associated with a lower risk of hyperkalemia than DPP-4 inhibitors in the overall population and across relevant subgroups. The consistency of associations among individual agents in the SGLT-2 inhibitor and GLP-1 receptor agonist classes suggests a class effect. These ancillary benefits of SGLT-2 inhibitors and GLP-1 receptor agonists further support their use in people with type 2 diabetes, especially in those at risk of hyperkalemia.

来源:BMJ,查看原文。版权归原作者所有。

参考来源

  1. Fu EL, Wexler DJ, Cromer SJ, et al. SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study. BMJ. 2024. PMID: 38925801. doi:10.1136/bmj-2023-078483

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。